Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses

Mutated proteins arising from somatic mutations in tumors are promising targets for cancer immunotherapy. They represent true tumor-specific antigens (TSAs) as they are exclusively expressed in tumors, reduce the risk of autoimmunity and are more likely to overcome tolerance compared to wild-type (w...

Descripción completa

Detalles Bibliográficos
Autores principales: Quandt, Jasmin, Schlude, Christoph, Bartoschek, Michael, Will, Rainer, Cid-Arregui, Angel, Schölch, Sebastian, Reissfelder, Christoph, Weitz, Jürgen, Schneider, Martin, Wiemann, Stefan, Momburg, Frank, Beckhove, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279329/
https://www.ncbi.nlm.nih.gov/pubmed/30524892
http://dx.doi.org/10.1080/2162402X.2018.1500671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279329/
https://www.ncbi.nlm.nih.gov/pubmed/30524892
http://dx.doi.org/10.1080/2162402X.2018.1500671

Ejemplares similares